Press & event

Vad händer?

Håll dig uppdaterad om våra senaste nyheter och event.

Displaying 1 - 10 of 122

Insights

Over the past decade the pharmaceutical industry has seen a surge in merger and acquisition (M&A) transactions. Among the several factors influencing consolidation, a primary driver of pharmaceutical M&A activity is the ability to minimise supply chain complexities. 

Insights

We have spent the last five years after the IPO building a global platform, getting a broad range of technologies and extending our customer base.

Insights

The enforcement of the EU Falsified Medicines Directive (FMD) in February 2019 saw the serialisation of pharmaceutical products become a legal requirement.

Insights

Industrialising inhalation products requires specialist knowledge, a comprehensive manufacturing strategy and comprehensive product maintenance in order to overcome potential hurdles during commercial scale production.

Insights

Archie Wall,  Karl Nicholls, Mikael B. Caspersen, Stig Skrivergaard,  Kenneth A. Howard,  Kersti Karu,  Vijay Chudasama and James R. Baker
  Org. Biomol. Chem., 2019, Advance Article

Insights

The advantages of modified release oral dosage forms

With the ability to control the rate and site of drug release to reach clinical objectives that cannot be achieved using conventional dosage forms, modified-release (MR) drug deli

Insights

While the development of new inhalation therapy drugs is growing in popularity, the tech transfer and scale-up stages present several complexities that are difficult for manufacturers to manage.

Insights

Following the enforcement of the EU Falsified Medicines Directive (FMD) in February 2019, serialisation is a legal requirement for pharmaceutical products.

Insights

The increasing potential of pulmonary routes of administration for local therapies is driving the development of inhalation drug products. However, developing treatments with this delivery mechanism presents several challenges for manufacturers.

Insights

The development of an antibody drug conjugate (ADC) is more unpredictable than that of a small molecule new chemical entity (NCE). As a result, the industry needs to invest in more vital research before conducting expensive clinical programs.